Qualification of Biomarkers for Drug Development in Organ Transplantation
Open Access
- 18 December 2007
- journal article
- editorial
- Published by Elsevier in American Journal of Transplantation
- Vol. 8 (2) , 267-270
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Implementing the U.S. FDA guidance on pharmacogenomic data submissionsEnvironmental and Molecular Mutagenesis, 2007
- Biomarker qualification pilot process at the US Food and Drug AdministrationThe AAPS Journal, 2007
- The Experience with Voluntary Genomic Data Submissions at the FDA and a Vision for the Future of the Voluntary Data Submission ProgramClinical Pharmacology & Therapeutics, 2007
- Paving the Critical Path: How can Clinical Pharmacology Help Achieve the Vision?Clinical Pharmacology & Therapeutics, 2007
- Protocol Biopsies in Renal Transplantation: Insights into Patient Management and PathogenesisAmerican Journal of Transplantation, 2007
- Biomarkers and Surrogate End Points for Fit-for-Purpose Development and Regulatory Evaluation of New DrugsClinical Pharmacology & Therapeutics, 2007
- Process Map Proposal for the Validation of Genomic BiomarkersPharmacogenomics, 2006
- Biomarkers and Surrogate Endpoints in Renal Transplantation: Present Status and Considerations for Clinical Trial DesignAmerican Journal of Transplantation, 2004
- Use of Biomarkers and Surrogate Endpoints in Drug Development and Regulatory Decision Making: Criteria, Validation, StrategiesAnnual Review of Pharmacology and Toxicology, 2001
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001